Origenis utilizes its patented drug discovery platform, MOREsystem, to combine drug design, patent analysis, chemical synthesis, and biological characterization. With a focus on anti-inflammatory and CNS drugs, Origenis offers early out-licensing opportunities and access to its proprietary patent database, Cippix. The company develops brain-penetrating, highly selective small molecule medicines and diagnostics for neurodegenerative and neuroinflammatory diseases. Their integrated lab space allows for efficient drug discovery services, including drug design, chemical synthesis, and biological characterization, through their technology platforms, MOREsystem and MolMind.